



# Errata

**Erratum. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. *Diabetes Care* 2017;40:1668–1677**

<https://doi.org/10.2337/dc18-er04>

In the article cited above, Fig. 3 was updated: the number 5 in the x-axis of panels A and B were deleted. Also, two consecutive sentences on page 1675 were revised to read: . . . NGR was greatest in the quartile at lowest risk of progressing to DM (35 vs. 17% and difference of 18%). In those at highest risk of progressing to DM, the corresponding rates were 24 and 11% (difference of 13%).

The online version (<https://doi.org/10.2337/dc17-1116>) has been corrected to reflect these changes.

*William H. Herman, Qing Pan, Sharon L. Edelstein, Kieren J. Mather, Leigh Perreault, Elizabeth Barrett-Connor, Dana M. Dabelea, Edward Horton, Steven E. Kahn, William C. Knowler, Carlos Lorenzo, Xavier Pi-Sunyer, Elizabeth Venditti, and Wen Ye, for the Diabetes Prevention Program Research Group*

**Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. *Diabetes Care* 2011;34:1785–1787**

<https://doi.org/10.2337/dc18-er04a>

In the article cited above, the last paragraph of the RESULTS section was corrected to read: The application of the DPTRS is presented in the following hypothetical example. An 8-year-old with a BMI of 18.0 kg/m<sup>2</sup> (log = 2.89) has normal glucose tolerance with fasting, 30-, 60-, 90-, and 120-min values of 80 mg/dL, 150 mg/dL, 160 mg/dL, 140 mg/dL, and 120 mg/dL, respectively. Fasting, 30-, 60-, 90-, and 120-min C-peptide values are 0.86 ng/mL (log = –0.151), 2.5 ng/mL, 3.1 ng/mL, 3.2 ng/mL, and 2.8 ng/mL, respectively. Using the DPTRS coefficients and the above information, the DPTRS value equals (1.569 × log BMI) + (–0.056 × age) + (0.813 × glucose sum from 30 to 120 min/100) + (–0.848 × C-peptide sum from 30 to 120 min/10) + (0.476 × log fasting C-peptide) = 7.66. This converts to a 3-year risk estimate of 0.59.

The online version (<https://doi.org/10.2337/dc11-0641>) has been corrected to reflect these changes.

*Jay M. Sosenko, Jay S. Skyler, Jeffrey Mahon, Jeffrey P. Krischer, Craig A. Beam, David C. Boulware, Carla J. Greenbaum, Lisa E. Rafkin, Catherine Cowie, David Cuthbertson, Jerry P. Palmer, and the Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups*